Parkinson's: Sniff test could predict risk up to a decade earlier

New study suggests that a test of olfaction could determine a person's risk of developing Parkinson's disease up to 10 years before a diagnosis.
Source: Parkinson's Disease News From Medical News Today - Category: Neurology Tags: Parkinson's Disease Source Type: news

Related Links:

In this study, we generate isogenic 3D midbrain organoids with or without a Parkinson's disease-associated LRRK2 G2019S mutation to study the pathogenic mechanisms associated with LRRK2 mutation. We demonstrate that these organoids can recapitulate the 3D pathological hallmarks observed in patients with LRRK2-associated sporadic Parkinson's disease. Importantly, analysis of the protein-protein interaction network in mutant organoids revealed that TXNIP, a thiol-oxidoreductase, is functionally important in the development of LRRK2-associated Parkinson's disease in a 3D environment. These results provide proof of princi...
Source: Stem Cell Reports - Category: Stem Cells Source Type: research
Publication date: Available online 21 February 2019Source: Neurochemistry InternationalAuthor(s): Huihan Ma, Yang Liu, Lin Tang, Hao Ding, Xuxia Bao, Fang Song, Min Zhu, Wenwei LiAbstractPrevious investigations have implicated mitochondrial dysfunction characterized by Complex I deficiency in the death of dopaminergic neurons in Parkinson's disease (PD). To date, there are no efficient therapeutic approaches to rescue mitochondrial respiratory impairment or prevent neurodegeneration in PD. The beneficial effects of echinacoside (ECH) on neurodegeneration have been reported in both in vivo and in vitro studies, yet the mech...
Source: Neurochemistry International - Category: Neuroscience Source Type: research
Publication date: Available online 21 February 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseAuthor(s): Hu Wang, Fanny Cheung, Anna C. Stoll, Patricia Rockwell, Maria E. Figueiredo-PereiraAbstractMitochondrial impairment and calcium (Ca++) dyshomeostasis are associated with Parkinson's disease (PD). When intracellular ATP levels are lowered, Ca++-ATPase pumps are impaired causing cytoplasmic Ca++ to be elevated and calpain activation. Little is known about the effect of calpain activation on Parkin integrity. To address this gap, we examined the effects of mitochondrial inhibitors [oligomycin ...
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - Category: Molecular Biology Source Type: research
Condition:   Parkinson Disease Intervention:   Other: Mediterranean Diet Sponsor:   University of Florida Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Cambridge startup Voyager Theraupetics ’ stock shot up nearly 25 percent Friday after it announced a second partnership deal with AbbVie to develop gene therapies for Parkinson’s disease.  Voyager (Nasdaq: VYGR) is expanding its partnership with pharmaceutical company AbbVie (NYSE: ABBV), launching a research effort to develop anti body treatments that can be delivered directly to the brain and target a protein called alpha-synuclein that has been linked to Parkinson's. AbbVie is paying the…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
The objective of this study was thus to determine whether fatigue in PD was associated with structural changes in gray or white matter and explore whether these changes were similar in older adults without PD. Magnetic resonance imaging (T1 weighted) and diffusion tensor imaging were performed in 60 patients with PD (17 females; age = 67.58 ± 5.51; disease duration = 5.67 ± 5.83 years) and 41 age- and sex- matched healthy controls. FSL image processing was used to measure gray matter volume, fractional anisotropy, and leukoariosis differences. Voxel-based morphometry confirmed gray matter lo...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
Authors: Chen Y, Zheng X, Wang Y, Song J Abstract Effect of PI3K/Akt/mTOR signaling pathway on the expression of JNK3 in Parkinsonian rats was investigated. A total of 200 rats were used for Parkinson's disease (PD) modeling and 180 models were successfully established. Rats were randomly divided into four groups including A, B, C, and D, 45 in each group. Group A was control group and no inhibitor was given. Group B was given PI3K inhibitor LY294002. Group C was given rapamycin inhibitor rapamycin; and group D was given inhibitor LY294002 and inhibitor rapamycin. JNK3 mRNA expression was detected by RT-qPCR and ex...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
In conclusion, cholinesterase inhibitors and memantine have an effect not only on global cognitive function and motor function, but also on attention, processing speed, executive functions, memory and language. However, careful monitoring of the side effects of rivastigmine may be required. Further clinical trials are required to verify these conclusions. PMID: 30783428 [PubMed]
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
People with Parkinson's disease (PD) treated with deep brain stimulation (DBS) with non-rechargeable implantable pulse generators (IPGs) require elective IPG replacement operations involving surgical and anesthesiologic risk. Life expectancy and the number of replacements per patient with DBS are increasing.
Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation - Category: Neurology Authors: Source Type: research
Tyrosyl-DNA phosphodiesterase 2 (TDP2) is a multifunctional protein that has been implicated in a myriad of cellular pathways. Although most well-known for its phosphodiesterase activity removing stalled topoisomerase 2 from DNA, TDP2 has also been shown to interact with both survival and apoptotic mitogen-activated protein kinase (MAPK) signaling cascades. Moreover, it facilitates enterovirus replication and has been genetically linked to neurological disorders ranging from Parkinson's disease to dyslexia. To accurately evaluate TDP2 as a therapeutic target, we need to understand how TDP2 performs such a wide diversity of...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Cell Biology Source Type: research
More News: Parkinson's Disease | Study